AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04164771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training and Moringa Oleifera
Description: Aerobic exercises/training refers to any type of rhythmic, continuous physical activities that use large group of muscles like walking, running, cycling, and swimming consuming additional amount of energy while Moringa Oleifera a plant from the family Moringacea, its products are used as a health supplement introduced in Africa and south Asian countries to cure many diseases and improve health status
Study NCT04137393 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: brushing
Description: mechanical and chemical plaque removal
Study NCT04137393 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: brushing
Description: mechanical and chemical plaque removal
Study NCT05052164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten-free nutrition plan + exercise group
Description: Menopausal or post-menopausal celiac women will follow a physical exercise program 3/4 times per week and their dietary intake will be gluten-free isocaloric
Study NCT05052164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gluten-free nutrition plan group
Description: Menopausal or post-menopausal celiac women will follow a gluten-free isocaloric dietary program
Study NCT05052164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Celiac controls group
Description: Menopausal or post-menopausal celiac women in whom all the tests were measured but they did not perform an intervention program with physical exercise or special follow-up of an adapted dietary-nutritional program
Study NCT03802370 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: connective tissue grafting by Dome Technique
Description: The dome technique addresses the placement of the CT, as it is layered over the implant and takes the shape of an inverted dome
Study NCT03458871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-week TTNS home-based protocol
Description: 4-week TTNS home-based protocol. Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is not contraction seen, maximal tolerable intensity will be used.~In addition, if the patient perceives pain, the intensity will be lowered until comfortable.~Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used.
Study NCT03415997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iohexol
Description: Iodinated contrast media
Study NCT00910364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise
Study NCT03688373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy (1 relating to least fearful and 10 indicating most fearful situation), formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises in either big or small steps.
Study NCT00709553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Study NCT00709553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: ZD4054 10 mg od
Study NCT03255148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Syntocinon nasal spray
Study NCT03255148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray
Study NCT02853500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriNav
Description: TriNav is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
Study NCT02853500 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Delivery
Description: Low profile tubing microcatheter for easier access to more peripheral/distal vascular branches for precise targeted delivery of medications.
Study NCT02853500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Medication used in cancer chemotherapy, including intraarterial delivery for liver malignancies.
Study NCT02853500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Medication used in cancer chemotherapy, including intraarterial delivery for liver malignancies.
Study NCT00710229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal injection
Study NCT00710229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: intravitreal injection
Study NCT01048437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transplant education with video
Description: 1 hour standard transplant module is replaced with the Explore Transplant presentation and 20 minute video featuring transplant patients and donors
Study NCT01048437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transplant education with speakers
Description: 1 hour standard transplant module is replaced with the Explore Transplant presentation and 3 live speakers: 1 deceased donor recipient, 1 living donor recipient and 1 living donor
Study NCT04438005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: ICP-022 is a white, round, uncoated tablet, 50 mg. It is administered orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
Study NCT03097120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.625 mg of conjugated equine estrogen
Description: one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily
Study NCT03097120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate
Description: one tablet of 0.625 mg of conjugated equine estrogen plus one tablet 2.5 mg of medroxyprogesterone acetate daily
Study NCT03097120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablets
Description: two placebo tablets daily
Study NCT01850420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-1
Study NCT02769208 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Central air handling unit air purification technologies
Description: As described in the arm descriptions, the interventions involve changing the baseline pre-filter + HEPA + ESP conditions by removing either just the ESP or both the ESP and the HEPA for a five week period.
Study NCT02199392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
Study NCT03187002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy-documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.
Study NCT03187002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate IV Sedation
Description: IV sedation with fentanyl and versed
Study NCT03187002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SHAM: Transcutaneous electrical nerve stimulation (TENS)
Description: Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding
Study NCT03187002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SHAM: Moderate IV Sedation
Description: Sham IV to ensure blinding
Study NCT00389636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TheraGauze
Description: TheraGauze
Study NCT00389636 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regranex
Description: Regranex + TheraGauze
Study NCT02154308 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL
Description: IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
Study NCT02175264 — intervention group
Intervention type: GENETIC
Intervention: Blood sample
Study NCT04913909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Effects of an oral probiotic or placebo use on oral microbiota and glycemic index in Type 2 diabetic patients
Description: The participants were randomized to the interventional groups, probiotic or placebo, by the diabetes nurse. During the intervention period of 30 nights, the participants were asked to let one Dentoblis™ or placebo lozenge slowly melt in their mouth for one minute before going to bed and after tooth brushing. Dentoblis™, as a test lozenge, contains 4x109 CFU/g S. salivarius M18 strain isolated from a healthy oral microbiota and has been utilized as oral probiotic inhibiting dental caries-causing pathogens.~The placebo is indistinguishable in form, size, color, and taste from the probiotic lozenge, but contains no bacteria. Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code. Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse.
Study NCT04913909 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Effects of an oral probiotic or placebo use on oral microbiota and glycemic index in Type 2 diabetic patients
Description: The participants were randomized to the interventional groups, probiotic or placebo, by the diabetes nurse. During the intervention period of 30 nights, the participants were asked to let one Dentoblis™ or placebo lozenge slowly melt in their mouth for one minute before going to bed and after tooth brushing. Dentoblis™, as a test lozenge, contains 4x109 CFU/g S. salivarius M18 strain isolated from a healthy oral microbiota and has been utilized as oral probiotic inhibiting dental caries-causing pathogens.~The placebo is indistinguishable in form, size, color, and taste from the probiotic lozenge, but contains no bacteria. Placebo and probiotic lozenges were equivalent to 810 mg each and containing same amount of xylitol. Both were provided by the manufacturer, Bluestone Pharma GmbH, Baar, Switzerland, in equal white containers boxes, separated by production code. Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse.
Study NCT01238237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Superselective Intraarterial Cerebral Infusion of Cetuximab
Description: Intraarterial Mannitol 25% 3-10 ml to open the blood brain barrier followed by Intraarterial Cetuximab single dose (starting at 100mg/m2 and escalating up to 500mg/m2)
Study NCT04752748 — intervention group
Intervention type: DRUG
Intervention: Drug protocol
Description: The following drug scheme was carried out: The patients began with methotrexate (MTX) 15 mg / week, which was increased to 25 mg / week until week 12. Subsequent steps for patients with an insufficient response (DAS28 score> 3.2 and the Physician's Global Assessment (PGA)> 4.0 \[0-10 cm\]) were leflunomide 20mg / day with MTX 15 mg / week from week 12 to week 24 and adalimumab twice a month and MTX 15mg / week from week 24 to week 48. The use of 5mg folic acid was advised once a week during the 48 weeks of the study. Three treatment failures were considered over these 48 weeks:~* Failure 1: failure of the first DMARD (MTX) in week 12.~* Failure 2: failure of the second DMARD (leflunomide) at week 24~* Failure 3: failure of the first immunobiological (adalimumab) at week 48.
Study NCT00872079 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Genomics
Description: Model predictive control is a computer based algorithm that can be applied to drug dosing. This computer tool uses a model of how a patient will respond to a drug dose based on demographic and historical dosing information to predict a new drug response. A drug dose controller applies all possible doses to the response model and selects the one dose that best meets the stated goals of the drug therapy. In the case of warfarin, we will calculate an international normalized ratio (INR) value within a specific target range.
Study NCT00674999 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion
Description: Application of Amnion with processing procedures involving the use of trypsin-EDTA
Study NCT00674999 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion
Description: Application of Amnion with processing procedures involving the use of Dispase II
Study NCT00674999 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polysporin/Bacitracin/Mycostatin
Description: Application of Prepared antibiotic ointment: Polysporin, Bacitracin and Mycostatin combined
Study NCT01384838 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Description: Nutritional, lifestyle and sports counseling
Study NCT01384838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: counseling and controlled physical activity
Study NCT00543309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesiritide
Description: Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted
Study NCT00543309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: milrinone
Description: Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted
Study NCT00543309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo bolus on CPB, then placebo infusion
Study NCT00741663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone and furosemide
Description: Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.
Study NCT00741663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone and furosemide
Description: Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
Study NCT00741663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone and furosemide
Description: Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
Study NCT01856309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg
Description: Sirukumab 100 mg subcutaneously (SC) at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 2, and every 2 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
Study NCT01856309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg
Description: Sirukumab 50 mg SC at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 4, and every 4 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
Study NCT01856309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.
Study NCT03370068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICSI
Description: Oocytes retrieved from one ovary will undergo insemination by ICSI.
Study NCT03370068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional IVF
Description: Oocytes retrieved from the second ovary will undergo insemination by conventional IVF
Study NCT00581646 — intervention group
Intervention type: BEHAVIORAL
Intervention: survey instrument
Description: Participants will be mailed or given a one time survey instrument and data will be collected either in person or by telephone. We expect the study survey to take approximately 35-45 minutes to complete. The domains assessed will include psychological functioning, reproductive knowledge, perception of third party reproduction and concerns, sexual functioning, and quality of life.
Study NCT01661452 — intervention group
Intervention type: OTHER
Intervention: Referral to counseling services if desired
Study NCT04519437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933+REGN10987
Description: Administered subcutaneous (SC) every 4 weeks (Q4W)
Study NCT04519437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneous (SC) every 4 weeks (Q4W)
Study NCT02348385 — intervention group
Intervention type: DRUG
Intervention: Amphetamine
Description: Subjects will have 2 PET scans on the same day. Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.
Study NCT01578837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginseng
Description: 2.25g of encapsulated ginseng (1.5g American Ginseng and 0.75g Rg3-enriched Korean Red Ginseng)will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
Study NCT01578837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Bran
Description: 2.25g of encapsulated 100% natural wheat bran will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
Study NCT02800798 — intervention group
Intervention type: OTHER
Intervention: Preeclampsia positive
Study NCT03164772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: anti-PD-L1
Study NCT03164772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: anti-CTLA-4
Study NCT03164772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI 1361849
Description: mRNA Vaccine
Study NCT03164772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PharmaJet Tropis® device
Description: The PharmaJet Tropis® device was used for the intradermal administration of the BI 1361849 vaccine components.
Study NCT02920996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Merestinib is a potent and selective type II MET/RON kinase inhibitor with the ability to achieve inhibition of MET activity both in vitro and in vivo.
Study NCT00243932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: coenzyme Q10
Description: antioxidant and mitochondrial cofactor, given in capsules three times daily
Study NCT00243932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules, indistinguishable from CoQ10 capsules, given three times daily
Study NCT02745522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT02745522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01697696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
Study NCT01697696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long-acting beta 2-agonist (LABA)
Description: QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
Study NCT01697696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match QAB149
Study NCT03608878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adagloxad simolenin/OBI-821
Description: Adagloxad simolenin (OBI-822) is a glyco-conjugated protein comprised of a carbohydrate tumor antigen. Globo H allyl glycoside is covalently linked to a carrier protein KLH, presented in a dominant trimer form with molecular weight between 1200-1395 kDa., to form Adagloxad simolenin (OBI-822) (Globo H-KLH) OBI-821 is a saponin based adjuvant structurally similar to descriptions found in the literature for another adjuvant, QS-21.~Adagloxad simolenin will be mixed with OBI-821 before administration.
Study NCT03608878 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Transarterial chemoembolization